|Chris Pillar, Director of Science and Operations|
Pillar, C.M., L.D. Hazlett, J.A. Hobden. Alkaline protease-deficient mutants of Pseudomonas aeruginosa are virulent in the eye. Curr Eye Res 2000; 21:730-9. Pillar, C.M, J.A. Hobden. Pseudomonas aeruginosa exotoxin A and keratitis in mice. Invest Ophthalmol Vis Sci 2002; 43:1437-44. Rumpel, S.*, A. Razeto A*, C.M. Pillar*, V. Vijayan, A. Taylor, K. Giller, M.S. Gilmore, S. Becker, M. Zweckstetter,. Structure and DNA-binding properties of the cytolysin regulator CylR2 from Enterococcus faecalis. EMBO J 2004; 23:3632-42. *authors of equal contribution Coburn, P.S., C.M. Pillar, B.D. Jett, W. Haas, M.S. Gilmore. Enterococcus faecalis senses target cells and in response expresses cytolysin. Science 2004; 306:2270-2. Draghi, D. C., B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52:2383-8. Draghi, D. C., B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 2008; 62:116-21. Pillar, C. M., M. K. Aranza, D. Shah, and D. F. Sahm. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. 2008; J Antimicrob Chemother 61:595-602. Pillar, C. M., D. C. Draghi, M. J. Dowzicky, and D. F. Sahm. In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest. J Clin Microbiol 2008; 46:2862-7. Pillar, C. M., D. C. Draghi, D. J. Sheehan, and D. F. Sahm. Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs. 2008; Diagn Microbiol Infect Dis 60:221-4. Pillar, C. M., M. K. Torres, N. P. Brown, D. Shah, and D. F. Sahm. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. 2008; Antimicrob Agents Chemother 52:4388-99. Shaw, K. J., S. Poppe, R. Schaadt, V. Brown-Driver, J. Finn, C. M. Pillar, D. Shinabarger, and G. Zurenko. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. 2008; Antimicrob Agents Chemother 52:4442-7. Arhin, F. F., D. C. Draghi, C. M. Pillar, T. R. Parr, Jr., G. Moeck, and D. F. Sahm. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. 2009; Antimicrob Agents Chemother 53:4762-71. Pillar, C. M., L. Goby, D. Draghi, P. Grover, and C. Thornsberry. Evaluating the in vitro susceptibility of bovine mastitis pathogens to a combination of kanamycin and cefalexin: Recommendations for a disk diffusion test. 2009; J Dairy Sci 92:6217-27. Haas, W., C. M. Pillar, G. E. Zurenko, J. C. Lee, L. S. Brunner, and T. W. Morris. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 2009; 53:3552-60. Haas, W., C. M. Pillar, C. K. Hesje, C. M. Sanfilippo, and T. W. Morris. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother 2010;65:1441-7. Arhin, F. F., G. Moeck, D. C. Draghi, C. M. Pillar, and D. F. Sahm. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008. Int J Antimicrob Agents 2010;36:474-6. Haas, W., C. M. Pillar, M. Torres, T. W. Morris, and D. F. Sahm..Monitoring Antibiotic Resistance in Ocular Microorganisms: Results from the Antibiotic Resistance Monitoring in Ocular MicRorganisms (ARMOR) 2009 Surveillance Study. Am J Ophthalmol. 2011 Haas, W., C. M. Pillar, C. K. Hesje, C. M. Sanfilippo, and T. W. Morris. In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride. J Antimicrob Chemother 2011;66:840-4. Davies TA, Queenan AM, Morrow BJ, Shang W, Amsler K, He W, Lynch AS, Pillar C, Flamm RK Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.J Antimicrob Chemother. 2011 Jul 20.
WMed Innovation Center
4717 Campus Drive Center
Kalamazoo, MI 49008